S
Steven E. Kalloger
Researcher at University of British Columbia
Publications - 8
Citations - 838
Steven E. Kalloger is an academic researcher from University of British Columbia. The author has contributed to research in topics: Ovarian cancer & Airway. The author has an hindex of 8, co-authored 8 publications receiving 764 citations. Previous affiliations of Steven E. Kalloger include Vancouver General Hospital.
Papers
More filters
Journal ArticleDOI
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
Katy Milne,Martin Köbel,Steven E. Kalloger,Rebecca O Barnes,Dongxia Gao,C. Blake Gilks,Peter H. Watson,Peter H. Watson,Peter H. Watson,Brad H. Nelson,Brad H. Nelson,Brad H. Nelson +11 more
TL;DR: Host immune responses to EOC vary widely according to histological subtype and the extent of residual disease, and TIA-1, FoxP3 and CD20 emerge as new positive prognostic factors in high-grade serous EOC from optimally debulked patients.
Journal ArticleDOI
Quantitative assessment of airway remodeling using high-resolution CT.
Yasutaka Nakano,Nestor L. Müller,Gregory G. King,Akio Niimi,Steven E. Kalloger,Michiaki Mishima,Peter D. Paré +6 more
TL;DR: It is shown that, by quantifying both the extent of emphysema and of airway remodeling, CT is useful in differentiating COPD patients who have primarily parenchymal disease from those who have mainly airway pathology.
Journal ArticleDOI
Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems.
Abdulmohsen Alkushi,Zainab H Abdul-Rahman,Peter Lim,Michael Schulzer,Andrew J. Coldman,Steven E. Kalloger,Dianne Miller,C. Blake Gilks +7 more
TL;DR: The proposed grading system was found to be an independent predictor of patient outcome when patient survival was adjusted for FIGO stage, patient age, and tumor cell type, and had more prognostic power than other grading systems tested.
Journal ArticleDOI
Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
Kate O’Connor,Hector Li-Chang,Steven E. Kalloger,Renata D'Alpino Peixoto,Douglas L. Webber,David A. Owen,David K. Driman,Richard Kirsch,Stefano Serra,Charles H. Scudamore,Daniel J. Renouf,David F. Schaeffer +11 more
TL;DR: On multivariable analysis, tumor budding was prognostically significantly independent of stage, grade, tumor size, nodal status, lymphovascular invasion, and perineural invasion.
Journal ArticleDOI
Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Katy Milne,Rebecca O Barnes,Adam Girardin,Adam Girardin,Melanie A. Mawer,Nancy J. Nesslinger,Alvin Ng,Julie S. Nielsen,Robert A. Sahota,Eric Tran,Eric Tran,John R. Webb,John R. Webb,May Q. Wong,Darin A. Wick,Andrew Wray,Elissa McMurtrie,Martin Köbel,Steven E. Kalloger,C. Blake Gilks,Peter H. Watson,Peter H. Watson,Peter H. Watson,Brad H. Nelson,Brad H. Nelson,Brad H. Nelson +25 more
TL;DR: Tumor-infiltrating CD8+ T cells are correlated with prolonged progression-free and overall survival in epithelial ovarian cancer and autoantibody and T cell responses may be correlated in EOC and directed toward the same antigens.